Tenet Healthcare Beats Peers in Q2, Still Trades at 12x Earnings

NEW YORK, August 5 —

Tenet Healthcare Corporation (THC) topped every hospital chain peer in Q2 2026 earnings while still trading at 12.3x forward P/E.

What Actually Happened

Being the top-ranked name in a sector during earnings season is a different signal than simply beating consensus. It means the operating model outperformed peers at the same macro moment, in the same labor cost environment, against the same reimbursement calendar. THC delivered that in Q2 2026.

The financials underneath that rank deserve a closer look. Revenue of $21.8bn TTM grew 6.8% YoY, and free cash flow landed at $2.2bn. Trailing EPS of $26.22 against a $253.33 share price implies a trailing P/E of roughly 9.7x, below the already-modest 12.3x forward figure. That 9.7x trailing multiple is low for any hospital operator not under active regulatory or reimbursement pressure. The 90-day chart, with the Q2 earnings event marked, captures where that price sits against recent history and how much of the beat has actually been priced in.

The wire story leads with the peer rank. The detail that gets less attention is $2.2bn in free cash flow. At this stock price, that figure suggests the company is generating capital at a rate the current multiple understates.

The Catch

The peer-group rank and headline valuation are confirmed. The specific margin and same-hospital volume data from the Q2 filing are not in the available inputs, and those numbers matter. Hospital chain earnings can look clean on revenue while absorbing labor cost pressure that only surfaces in EBITDA margins. A 12.3x forward P/E assumes the earnings trajectory holds; any Q3 guidance cut on same-hospital revenue growth or adjusted EBITDA margin narrows the distance between "cheap" and "value trap" quickly.

A low multiple on a top performer is only durable if the cost structure holds. That answer waits until Q3. For context on how to read between the lines of a quarterly filing, see the guide on how to read an earnings report.

Bottom Line

This is a value investor's setup after Q2, not a momentum trade. A top peer-group rank at a sub-10x trailing multiple with $2.2bn in FCF is unusual in healthcare. Run the $2.2bn FCF base through the DCF calculator to stress-test what "cheap" actually holds at different growth assumptions before calling this a buy.

The one number to watch next quarter: same-hospital revenue growth. If it's positive and margins hold, the 12.3x forward P/E looks like a persistent mismatch the market is slow to close. For a deeper look at how THC stacked up against the field, see how ambulatory care offset hospital risks in the Q2 beat. For the full fundamentals and a generated equity report, visit the Tenet Healthcare stock page on Basis Report.

Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.